Wall Street analyst estimates for Gelteq Limited Ordinary Shares (GELS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -5.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $147536 | $79843 | 0 | $165645 |
| Cost of Revenue | 0 | 0 | $94874 | $48925 | 0 | 0 |
| Gross Profit | 0 | 0 | $52662 | $30918 | 0 | $165645 |
| Research & Development | $342357 | $277055 | $529017 | $665035 | $276057 | $628606 |
| Selling, General & Admin | $230521 | $463733 | $1.5M | $1.7M | $1.3M | $2.2M |
| Operating Expenses | $529620 | $647624 | $3.2M | $3.1M | $2.9M | $5.7M |
| Operating Income | 0 | -$647624 | -$3.2M | -$3.1M | -$2.9M | -$5.5M |
| EBITDA | -$527233 | -$589679 | -$2.0M | -$1.9M | -$1.7M | -$3.5M |
| Interest Expense | 0 | $1297 | $174503 | $403521 | $585120 | $1.9M |
| Pre-tax Income | -$529620 | -$648921 | -$3.4M | -$3.5M | -$3.5M | -$6.6M |
| Income Tax | -$154033 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$375587 | -$648921 | -$3.4M | -$3.5M | -$3.5M | -$6.6M |
| EPS | $-0.16 | $-0.07 | $-0.36 | $-0.37 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.16 | $-0.07 | $-0.36 | $-0.37 | $0.00 | $0.00 |
| Shares Outstanding (Diluted) | $2.3M | $9.4M | $9.4M | $9.4M | 0 | 0 |
Price
| Price | $0.58 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | AU |
Related companies: AYTU · BFRG · BFRI · BGLC · COCP · EVGN · IMNN
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of GELS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks